Contact Us

CleanCap® mCherry mRNA (5moU) - (L-7203)

CleanCap® mCherry mRNA (5-methoxyuridine)
In stock
Product SKU Unit Size Price Qty
L-7203-100 100 µg
L-7203-1000 1 mg
L-7203-5 5 x 1 mg



mCherry mRNA encodes the fluorescent protein, mCherry, which is derived from DsRed, a protein found in Discosoma sp. mCherry is a monomeric fluorophore with a peak absorption at 587 nm and emission at 610 nm. It is stable and resistant to photobleaching.

This mRNA is capped using CleanCap® Reagent AG, TriLink's patented co-transciptional capping technology, which results in the naturally occurring Cap-1 structure with >95% capping efficiency. It is manufactured using TriLink’s CleanScript™ method*, polyadenylated, modified with 5-methoxyuridine, and optimized for mammalian systems. It mimics a fully processed mature mRNA.

CleanCap® Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA).

5-methoxyuridine is a modified uridine that can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression.

CleanScript™ method is TriLink’s proprietary in vitro transcription process that is optimized to minimize dsRNA formation and increase mRNA activity in vivo.

*Starting April 30th, 2024

Product details
Catalog No L-7203
Purity Passes Agarose Gel Mobility
Length 997 nucleotides
Base Composition Fully substituted with 5-Methoxy-U
Concentration 1.0 mg/mL
Buffer 1 mM Sodium Citrate pH 6.4
Conversion Factor 40 µg/OD260
Recommended Storage At or below -40°C
Application Reporter Genes
Cap AG Start, Cap 1, CleanCap
Other Name(s) CleanCap® mCherry mRNA (5-methoxyuridine)
Technical documents

Safety Data Sheet Look-up

L-7203 Product Insert

CleanCap mCherry ORF Sequence

Products faqs

They all contain an optimal 5′ Cap 1 found in higher eukaryotes for their functionality and stability. They also contain a synthetic 5′ UTR with a strong Kozak sequence for efficient translation and a 3′ UTR derived from mouse alpha-globin. Their key differences lie in the type of CleanCap® analog used and the sequence compositions, which may affect their protein expression and immunogenicity.


CleanCap® mRNAs

CleanCap® mRNAs (5moU)

CleanCap® M6 mRNAs (N1MePsU)

Expression system




5′ cap

Cap 1

Cap 1

Cap 1

Cap analog

CleanCap® AG

CleanCap® AG

CleanCap® M6

5′ and 3′ UTRs




Poly(A) tail

120 nt

120 nt

120 nt

Sequence composition

Unmodified uridines

Uridines substituted with 5-methoxyuridines

Uridines substituted with N1-methylpseudouridines

Protein expression









It is TriLink’s proprietary in vitro transcription method that produces high-quality, high-yield mRNAs from a broad range of sequences. It has been optimized to minimize dsRNA and improve in vivo protein expression from the resulting mRNAs. Please see here for more information.

Our catalog mRNAs are intended for research use and manufactured with procedures in place to minimize endotoxin exposure. However, they are manufactured outside of a cleanroom and thus are not released with an endotoxin specification.  If you need mRNA released with an endotoxin specification or a higher grade of material, please contact [email protected].

We recommend storing the mRNAs at -400 C to -800 C. To minimize freeze-thaw cycles, aliquot the sample into single-use quantities on the first usage. If kept under these conditions, our catalog mRNAs have been shown to maintain stability for at least 2 years.

The sequence reported is just the ORF, start codon to stop codon, for our catalog mRNAs. It does not include the proprietary 5′ UTR, 3′ UTR, or the 120-nt poly-A tail. For full mRNA length and the length of the ORF please see the corresponding product insert.

Our catalog mRNAs are purified through DNase treatment to remove DNA templates, diafiltration to remove salts and small molecules, and oligo dT capture to remove impurities and retain species with poly(A) tails. 

We do not carry Cy5-labeled mRNAs as catalog products. You may order them as a custom mRNA by completing this request form.

We use the dot blot test, which is a qualitative test to determine the relative amount of dsRNA present in a sample. Generally, this test is performed to assess dsRNA levels in mRNAs before and after RP-HPLC purification.

We minimize the dsRNA level in our ready-to-use mRNAs by incorporating stringent processes that consist of:

  • In vitro transcription using our proprietary CleanScript™ method or the CleanCap® M6 protocol
  • Multiple post-IVT purification steps

We also assess dsRNA level in the sample by dot blot as part of quality analysis.

We look for a single main band running to approximately the correct length to pass the gel result.  Some factors such as modified NTPs can make a sample run slightly lower than the expected size.  Sometimes, sequence-related factors such as highly repetitive or UTP-rich regions (especially when modified UTP is used) can result in additional bands.  We take account of all these factors to confirm that the mRNA was manufactured appropriately and the band is sequence specific before passing the results.

The fragment analyzer reports the percent of smear with a chromatogram. The smear analysis corresponds to the full-length integrity of an mRNA sample.

We start by cleaving the 5′ end of the mRNAs, then use LCMS to determine the mass of capped and uncapped species by the following formula:

We use 40 as the extinction coefficient for our mRNAs. Assigning a sequence-specific extinction coefficient for mRNA can be problematic due to its dependence on length and sequence composition.  Factors like final buffer and temperature can also impact results.  Thus, it is standard to use 40 for all mRNA species and not to calculate a coefficient for each sequence as you would with an oligonucleotide.

Certificate of analysis

CoA search tool

Intellectual property

CleanCap capping technology For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at Patents and patent pending, see

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

  1. Ball, Rebecca L.; Hajj, Khalid A.; Vizelman, Jamie; Bajaj, Palak; Whitehead, Kathryn A. . Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
  2. Matsui, Akitsugu; Uchida, Satoshi; Hayashi, Akimasa; Kataoka, Kazunori; Itaka, Keiji . Prolonged engraftment of transplanted hepatocytes in the liver by transient pro-survival factor supplementation using ex vivo mRNA transfection.
  3. Yasar, Hanzey; Biehl, Alexander; De Rossi, Chiara; Koch, Marcus; Murgia, Xabi; Loretz, Brigitta; Lehr, Claus-Michael . Kinetics of mRNA delivery and protein translation in dendritic cells using lipid-coated PLGA nanoparticles.
  4. Del Valle Morales, D;Trotman, JB;Bundschuh, R;Schoenberg, DR; . Inhibition of cytoplasmic cap methylation identifies 5' TOP mRNAs as recapping targets and reveals recapping sites downstream of native 5' ends
  5. Wang, Y;Shahi, PK;Wang, X;Xie, R;Zhao, Y;Wu, M;Roge, S;Pattnaik, BR;Gong, S; . In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles
  6. Bratkowski, M;Xie, T;Thayer, DA;Lad, S;Mathur, P;Yang, YS;Danko, G;Burdett, TC;Danao, J;Cantor, A;Kozak, JA;Brown, SP;Bai, X;Sambashivan, S; . Structural and Mechanistic Regulation of the Pro-degenerative NAD Hydrolase SARM1
  7. Patel, S;Ryals, RC;Weller, KK;Pennesi, ME;Sahay, G; . Lipid nanoparticles for delivery of messenger RNA to the back of the eye
  8. Lissandrello, CA;Santos, JA;Hsi, P;Welch, M;Mott, VL;Kim, ES;Chesin, J;Haroutunian, NJ;Stoddard, AG;Czarnecki, A;Coppeta, JR;Freeman, DK;Flusberg, DA;Balestrini, JL;Tandon, V; . High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing
  9. Pusic, KM;Kraig, RP;Pusic, AD; . IFN?-stimulated dendritic cell extracellular vesicles can be nasally administered to the brain and enter oligodendrocytes
  10. Ross-Thriepland, D;Bornot, A;Butler, L;Desai, A;Jaiswal, H;Peel, S;Hunter, MR;Odunze, U;Isherwood, B;Gianni, D; . Arrayed CRISPR Screening Identifies Novel Targets That Enhance the Productive Delivery of mRNA by MC3-Based Lipid Nanoparticles
  11. Del Valle Morales, D;Schoenberg, DR; . Analyzing (Re)Capping of mRNA Using Transcript Specific 5' End Sequencing
  12. Carreiro, MJCCR; . New hepatic cell lines for research, drug testing and vaccine development: Molecular tools for high-throughput screening of HCV replicating cells
  13. Robinson, E; . Optimizing Gene Delivery for an Early Cancer Detection Strategy
  14. Nasr, SS;Lee, S;Thiyagarajan, D;Boese, A;Loretz, B;Lehr, CM; . Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems
  15. Zhang, H;Bussmann, J;Huhnke, FH;Devoldere, J;Minnaert, AK;Jiskoot, W;Serwane, F;Spatz, J;R . Together is Better: mRNA Co-Encapsulation in Lipoplexes is Required to Obtain Ratiometric Co-Delivery and Protein Expression on the Single Cell Level
  16. Hao, S;Inamdar, VV;Sigmund, EC;Zhang, F;Stephan, SB;Watson, C;Weaver, SJ;Nielsen, UB;Stephan, MT; . BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology
Show more